Cellectis Starts BPDCN Phase I Trial with Gene Edited CAR-T Cell Therapy – Genetic Engineering & Biotechnology News (blog)
|
Cellectis Starts BPDCN Phase I Trial with Gene Edited CAR–T Cell Therapy
Genetic Engineering & Biotechnology News (blog) Cellectis reported that the first patient has been dosed in a Phase I clinical trial evaluating its TALEN® gene-edited CAR–T cell product UCART123 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The BPDCN study follows on from … |
